 RADNOR, Pa., Aug. 18, 2021 PRNewswire -- NRx Pharmaceuticals NRx NASDAQ: NRXP, a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMITM aviptadil which is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health. 